Clinical Study

Chemotherapy Administration during Pelvic Radiation for Cervical Cancer Patients Aged ≥ 55 Years in the SEER-Medicare Population

Table 4

Multivariate analysis for chemoradiation administration within 3 months after diagnosis in women with stages II-IVA cervical cancer from 1998 to 2002.

Patient and tumor characteristicsnumber of cases ( )Odds ratio* of chemoradiation95% Confidence interval

Age
55–70 years152 (39.5%)1
>71 years233 (60.5%)0.620.42–0.94

Stage
II213 (55.3%)1
III163 (42.3%)0.960.63–1.47
IVA9 (2.3%)0.590.14–2.50

Histology
Squamous289 (75.1%)1
Adenocarcinoma55 (14.3%)0.840.45–1.57
Adenosquamous13 (3.4%)0.530.16–1.78
Other28 (7.3%)0.610.26–1.43

Race
Caucasian237 (61.6%)1
African-American74 (19.2%)1.220.72–2.06
Other74 (19.2%)1.280.75–2.18

Residence
Big Metropolitan area235 (61.0%)1
Metropolitan area94 (24.4%)1.480.89–2.45
Urban, less urban, rural56 (14.5%)2.631.41–4.91

Socioeconomic status, median income
<30,70094 (24.4%)1
30,701–39,42593 (24.2%)0.770.47–1.28
39,426–53,707102 (26.5%)0.720.43–1.20
>53,70896 (24.9%)1.180.70–1.98

Comorbidity index, Charlson
0274 (71.2%)1
163 (16.4%)1.090.61–1.94
228 (7.3%)0.720.31–1.65
3+20 (5.2%)0.80.31–2.10

*Adjusted for variables listed in the tables.